FDA Errs On Estimates For NDIs, Claims Substantiation – CRN
This article was originally published in The Tan Sheet
Executive Summary
FDA “grossly underestimated” firms’ costs for filing new dietary ingredient notifications and ignored their costs for substantiating claims, the Council for Responsible Nutrition says in July 25 comments.
You may also be interested in...
Embria Studies FDA Expectations Before Successful EpiCor NDI
FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”
Embria Studies FDA Expectations Before Successful EpiCor NDI
FDA’s formal acknowledgment of Embria’s NDI notification for EpiCor comes after the firm called FDA early in the process to discuss the pending notification and worked to understand the agency’s expectations fully. Kevin Boot, Embria’s regulatory counsel, recommends simple notifications that are “readable by everyone.”
FDA Defends Estimate For NDI Notification Preparation
Supplement firms already should have compiled the information for a new dietary ingredient notification when they substantiated the safety of the ingredient, FDA says.